OncoTherapy Science (4564) AI Stock Analysis

• Market Cap: €8.13B
• Dividend Yield: N/A
• Average Volume (3M): 39.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: 99.87%
• EPS Growth: 40.60%
• Country: JP
• Employees: 54
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.13
• Shares Outstanding: 338,643,700
• 10 Day Avg. Volume: 60,218,049
• 30 Day Avg. Volume: 39,409,347
• PEG Ratio: 0.19
• Price to Book (P/B): 10.03
• Price to Sales (P/S): 9.75
• P/FCF Ratio: -8.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Neutral
• Price Target: ¥23.00 ▼(-4.17% Downside)

OncoTherapy Science's stock score is primarily impacted by its poor financial performance, characterized by persistent losses and cash flow issues. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data limits the analysis to these factors.

OncoTherapy Science Business Overview & Revenue Model

Company Description

OncoTherapy Science (4564) is a biopharmaceutical company focused on the development of innovative therapies for cancer treatment. The company operates primarily within the oncology sector, leveraging advanced research and technology to create targeted therapies aimed at improving patient outcomes. Its core products include a pipeline of novel drug candidates designed to address various types of malignancies, alongside ongoing collaborations in clinical trials and research initiatives.

How the Company Makes Money

OncoTherapy Science generates revenue through multiple channels, including the sale of its proprietary drug candidates, licensing agreements with larger pharmaceutical companies, and government or private research grants for ongoing clinical studies. The company also benefits from strategic partnerships with research institutions and healthcare organizations, which can lead to significant funding and shared resources. Additionally, milestone payments from collaborations and royalties from successful product commercialization contribute to its earnings.

OncoTherapy Science Financial Statement Overview

Summary

OncoTherapy Science faces significant financial challenges, with persistent losses and cash flow issues. The income statement reflects operational inefficiencies and erratic revenue growth. The balance sheet shows some equity strength but is overshadowed by liabilities and declining assets. Cash flow issues are concerning, with negative free cash flow and reliance on financing activities.

Income Statement

The company has experienced significant challenges in profitability, with consistently negative net and gross profit margins. Revenue growth is erratic, with fluctuations in revenue suggesting instability. EBIT and EBITDA margins have been consistently negative, indicating operational inefficiencies. Overall, the income statement reflects a struggling financial performance, typical in high-risk biotech ventures.

Balance Sheet

The balance sheet shows a relatively high equity ratio, supported by substantial stockholders' equity compared to total assets. However, the company carries significant liabilities, resulting in a moderate debt-to-equity ratio. The consistent decline in total assets and stockholders' equity over the years indicates potential risk. The company's ability to manage liabilities is crucial, given its negative equity growth trend.

Cash Flow

The cash flow statements reveal persistent negative free cash flow and operating cash flow, which are concerning for future liquidity. The company has relied heavily on financing activities to sustain operations, indicating potential challenges in sustaining cash flows from core operations. There is a lack of positive cash flow generation, which poses a risk to financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	851.24M	750.05M	610.12M	1.13B	1.15B	332.48M
Gross Profit	164.71M	-12.76M	-177.72M	41.69M	113.91M	19.54M
EBITDA	-842.06M	-811.92M	-1.29B	-1.09B	-2.04B	-1.59B
Net Income	-827.42M	-815.28M	-1.29B	-1.12B	-2.57B	-1.56B
Balance Sheet
Total Assets	1.53B	1.16B	867.27M	1.51B	2.69B	3.37B
Cash, Cash Equivalents and Short-Term Investments	1.23B	833.88M	527.66M	1.12B	1.84B	2.90B
Total Debt	37.14M	51.07M	106.85M	0.00	0.00	0.00
Total Liabilities	449.62M	426.09M	513.61M	656.27M	704.97M	291.28M
Stockholders Equity	1.08B	729.11M	353.67M	855.17M	1.98B	3.08B
Cash Flow
Free Cash Flow	0.00	-815.30M	-1.23B	-800.29M	-2.53B	-1.81B
Operating Cash Flow	0.00	-815.02M	-1.23B	-794.90M	-2.07B	-1.76B
Investing Cash Flow	0.00	-279.00K	-33.35M	-20.32M	-467.93M	-52.23M
Financing Cash Flow	0.00	1.12B	671.37M	95.95M	1.48B	0.00

OncoTherapy Science Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 24.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Neutral. The current price of 24 is above the 20-day moving average (MA) of 23.60, below the 50-day MA of 25.32, and below the 200-day MA of 25.78, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 49.18 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4564.

OncoTherapy Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4588	58 Neutral	¥22.91B	―	―	―	-9.04%	13.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4583	48 Neutral	¥8.71B	-8.16	―	―	30.92%	26.00%
4593	41 Neutral	¥53.92B	―	―	―	-78.54%	10.23%
4564	40 Neutral	€8.13B	-7.95	-63.25%	―	99.87%	40.60%
4881	38 Underperform	¥3.73B	-2.19	―	―	965.85%	-42.78%
4598	28 Underperform	¥6.04B	―	―	―	―	20.41%